Abstract
The clinical course in 4 patients with renal carcinoma stages II, III or IV subjected to periods of extracorporeal immunoadsorption is reported. By this technique we have previously demonstrated that it is possible to isolate and remove circulating tumour associated antigens from the blood stream. The removal of these antigens should, according to present-day concepts, make it possible to control "antigenic inhibition" and/or "blocking", thus facilitating the immune mediated destruction of residual tumour cells in advanced disease. The clinical course in these patients, however, did not differ from the expected clinical course in other such patients. The failure of extracorporeal immunoadsorption to alter the natural course of the disease may be due either to too large a tumour burden or to the possibility that spontaneous tumours during evolution and progression become independent of immune restrictions.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
